Search Results

Your search for Melanie Royce, MD, PhD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Monday, April 9, 2018 1:58 PM

mTOR Inhibitor Plus Endocrine Therapy in Postmenopausal Women With Advanced ER-Positive, HER2-Negative Breast Cancer

In the phase II BOLERO-4 trial reported in JAMA Oncology, Royce et al found that the combination of the mTOR inhibitor everolimus (Afinitor) and endocrine therapy was active in first-line treatment of postmenopausal women with advanced estrogen receptor (ER)-positive, human epidermal growth factor...

breast cancer

By The ASCO Post Staff / 2016 ESMO Congress

Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial

Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)

Apr

Today In Oncology

Search Results

Your search for Melanie Royce, MD, PhD matches 2 pages

mTOR Inhibitor Plus Endocrine Therapy in Postmenopausal Women With Advanced ER-Positive, HER2-Negative Breast Cancer

Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer